EUDA Health Holdings Limited (NASDAQ:EUDA - Get Free Report)'s share price fell 3.2% during mid-day trading on Thursday . The company traded as low as $3.62 and last traded at $3.68. 37,164 shares changed hands during trading, a decline of 55% from the average session volume of 82,335 shares. The stock had previously closed at $3.80.
EUDA Health Stock Up 1.6%
The company's 50 day moving average price is $3.82 and its two-hundred day moving average price is $4.07.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in EUDA Health stock. XTX Topco Ltd bought a new stake in shares of EUDA Health Holdings Limited (NASDAQ:EUDA - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 16,463 shares of the company's stock, valued at approximately $75,000. XTX Topco Ltd owned approximately 0.07% of EUDA Health at the end of the most recent reporting period. 4.35% of the stock is owned by hedge funds and other institutional investors.
EUDA Health Company Profile
(
Get Free Report)
EUDA Health Holdings Limited operates as a healthcare specialty company. The company operates through two segments, Medical Services and Property Management Services. It offers a range of specialty care services to patients; and operates medical facility general practice clinic that provides holistic care for various illnesses.
Featured Stories
Before you consider EUDA Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and EUDA Health wasn't on the list.
While EUDA Health currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
